Finally, a solution that's proven to treat your patient's pain.

After four weeks of taking Rightful every morning and evening, user’s days, nights, and lives were transformed.

 

DOWNLOAD REPORT

Rightful succeeds where other options have failed.

We create solutions to health problems that are either poorly addressed by conventional medicine, or where the answers we have are fraught with issues.

Our first product was formulated for the 100 million people who suffer from recurring pain and lack real, long-term solutions. We selected natural ingredients that are scientifically proven to be effective on their own, and created For Pain & Recovery, the first of its kind solution to address the multiple underlying problems of recurring pain.

Rightful

  • Promotes a healthy inflammatory response*
  • Protects the central nervous system and supports daily calm and focus*
  • Enhances recovery by providing relief of discomfort due to exercise, overwork or stress*
  • Reduces fatigue*
  • Improves energy levels, mood, and physical endurance*
  • Strengthens the ability to deal with stress*
  • Supports restful sleep*

Turmeric Rhizome

  • Study Details
    Sun J, Chen F, Braun C, et al. Role of curcumin in the management of pathological pain. Phytomedicine. 2018;48:129-140.
  • Study Design
    Review
  • Included Studies
    Pre-clinical and clinical studies
  • Study Duration
    Review of studies from 1976 to January 2018
  • Intervention(s)
    Curcumin
  • Control
    Various
  • Primary Outcomes
    Summarization of updated information on the traditional uses, chemical constituents and bioactivities of turmeric; highlighting the mechanisms of curcumin’s role and antinociceptive effects in pathological pain by sciatic nerve injury, spinal cord injury, diabetic neuropathy, alcoholic neuropathy, opioid tolerance or opioid-induced hyperalgesia, chemotherapy induced peripheral neuroinflammation.
  • Results and Conclusion(s)
    Curcumin plays a beneficial role in the treatment of pathological pain.  The clinical studies reviewed provide compelling evidence and justification for the use of curcumin as a therapeutic treatment for pain relief. Curcumin was shown to be generally well tolerated at high doses. The bioavailability of curcumin is addressed, including the use of adjuvants such as piperine and phospholipids. The authors recommend more high-quality clinical studies be undertaken to evaluate the clinical effectiveness of curcumin in subgroups of patients suffering from pathological pain.
  • Adverse Events
    Curcumin is generally well tolerated at high doses without toxic effects.
  • Summary
    This 2018 review summarized updated information on the traditional uses, chemical constituents, and bioactive compounds of turmeric, to explore its antinociceptive effects in pathological pain and evaluate future therapeutic opportunities. Both clinical and pre-clinical studies were included in the review dating from 1976 through January of 2018. Pathological pain was evaluated in relation to sciatic nerve injury, spinal cord injury, diabetic neuropathy, alcoholic neuropathy, opioid tolerance or opioid-induced hyperalgesia, and chemotherapy induced peripheral neuroinflammation. 

Turmeric (Curcumin)

  • Study Details
    Bannuru RR, Osani MC, Al-Eid F, Wang C. Efficacy of curcumin and Boswellia for knee osteoarthritis: Systematic review and meta-analysis. Seminars in Arthritis and Rheumatism. 2018;48(3):416-429.
  • Study Design
    Meta-Analysis and Systematic Review
  • Included Studies
    Randomized clinical trials: 11 studies included in meta-analysis 5 trials compared curcumin vs placebo 4 trails compared boswellia vs placebo 2 trials compared curcumin vs NSAID 3 trials compared curcumin and boswellia in combination vs placebo or NSAID
  • Study Duration
    4-24 weeks
  • Intervention(s)
    Curcumin or boswellia products administered individually, or the combination of both
  • Control
    Placebo or NSAID
  • Primary Outcomes
    Measure of pain, function, adherence
  • Results and Conclusion(s)
    The reviewers from Tufts Medical Center concluded that curcumin and boswellia formulations were statistically significantly more effective than placebo for pain relief and functional improvement. Curcumin had similar efficacy outcomes to NSAIDs and participants taking curcumin were significantly less likely to experience gastrointestinal adverse events. There were no significant differences between curcumin, boswellia and placebo in safety outcomes. Reviewers suggest that curcumin or boswellia formulations could be a ‘valuable treatment for relieving symptoms of knee OA, while also reducing safety risk.’ Limitations of the review included a limited number of trials and small study sizes.
  • Adverse Events
    6 patients in the review reported adverse events in curcumin category: 5
  • Summary
    This 2018 systematic review and meta-analysis evaluated the efficacy of curcumin and/or boswellia for knee osteoarthritis (OA). Trials included in the review involved curcumin or boswellia individually as monotherapies and in combination, versus placebo or NSAIDs. Eleven randomized controlled trials were included in the meta-analysis.  Study durations ranged from 4 to 28 weeks with participants ranging from 28-331 patients.

Corydalis

  • Study Details
    Zuo, C, et al. Controlled clinical study on compound Decumbent Corydalis Rhizome and diclofenac in treatment of knee osteoarthritis.   (China Journal of Chinese Materia Medica) 2015 Jan;40(1):149-53.
  • Study Design
    Controlled clinical trial
  • Participants
    79 patients with knee osteoarthritis
  • Study Duration
    12 weeks
  • Intervention(s)
    Corydalis rhizome 1.8 g daily
  • Control
    Diclofenac sodium 75 mg per day used as an active control
  • Primary Outcomes
    Total efficacy, main efficacy indexes (pain on walking 20 min), minor indexes (tenderness on palpation, Western Ontario and McMaster Universities OA index (WOMAC) and Short-Form Health Survey (SF-36)
  • Results and Conclusion(s)
    Total efficacy improved by 68.2%/63.41% for corydalis group and 71.05%/63.16% for diclofenac group based on patient/physician evaluation. Both groups showed improvements in main efficacy and minor indexes. There was no significant difference between the two groups in total efficacy, main efficacy indexes, and minor indexes.
  • Adverse Events
    The percentage of adverse events was 24.39% in the corydalis group and 47.37% in the diclofenac group. The difference was significant (P < 0.05) and in favor of Corydalis.
  • Summary
    This was a controlled clinical trial evaluating the effects of Corydalis rhizome (1.8 g daily) on knee osteoarthritis in 79 patients over a 12-week period. The primary endpoint was reduction in pain as assessed by the total efficacy, main efficacy (pain on walking 20 min), and minor indexes (tenderness on palpation, Western Ontario and McMaster Universities OA index (WOMAC) and Short-Form Health Survey (SF-36). At the study’s conclusion, total efficacy improved by 68.2%/63.41% in the corydalis group and 71.05%/63.16% in the diclofenac group based upon patient/physician evaluation. Both groups showed improvement in main efficacy and minor indexes and there was no significant difference between the two groups in any of the indexes. The authors concluded that Corydalis “is as efficient as diclofenac sodium but more tolerable, with a good clinical application prospect.” 

Broad-Spectrum Hemp

  • Study Details
    Bruni N, et al. Cannabinoid delivery systems for pain and inflammation treatment. Molecules 2018 Oct;23(10):2478.
  • Study Design
    Review
  • Included Studies
    Pre-clinical to advanced clinical trials
  • Study Duration
    Varies
  • Intervention(s)
    Cannabis-based medicines, including cannabidiol
  • Control
    Adjunct or in place of other therapies, including anticonvulsants and antidepressants
  • Primary Outcomes
    Acute and chronic pain, including chronic inflammatory diseases (arthritis), neuropathic pain
  • Results and Conclusion(s)
    Moderate-quality evidence for cannabinoids use chronic pain and spasticity. Preclinical evidence that cannabidiol protects against intestinal inflammation.  Substantial evidence for cannabis use for chronic pain, including neuropathic pain.
  • Adverse Events
    “Cannabinoids were associated with an increased risk of short-term effects”
  • Summary
    This was a review evaluating the recent preclinical and advanced clinical trials on cannabis-based medicines, including cannabidiol, and pain and inflammation.    Patients with chronic Arthritic and musculoskeletal pain were reported to be the most prevalent users of cannabidiol products. Numerous preclinical studies have shown that cannabinoid receptor agonists block pain and attenuate inflammation. The latter may be due to cannabidiol’s ability to up-regulate cannabinoid receptor activity or increase endocannabinoid production.  Included in the review were 79 trials that “concluded that there was moderate-quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity.” Furthermore, preclinical evidence suggests that cannabidiol protects against inflammatory intestinal inflammation and may have a use in inflammatory bowel diseases. 

Black Pepper (Piperine)

  • Study Details
    Gorgani L, et al. Piperine-The Bioactive Compound of Pepper: From Isolation to Medicinal Formulations. Comprehensive Reviews in Food Science and Food Safety 2017; 16(1): 124-140. 
  • Study Design
    Review Paper
  • Included Studies
    12 human studies, 16 animal studies, nine in vitro studies
  • Study Duration
    Varies
  • Interventions
    Varies
  • Control
    Varies
  • Primary Outcomes
    Therapeutic effects, extraction methods, bio-enhancing ability of piperine on other ingredients (herbs, drugs) as well as improving piperine’s bioavailability.
  • Results and Conclusion(s)
    The strongest research supports the use of black pepper for its antioxidant and anti-inflammatory effects; piperine improves bioavailability and effects of curcumin in humans and animals; limited research shows that nanoparticles and lipid encapsulations improve bioavailability of piperine.
  • Adverse Events
    No adverse events were reported up to 50 mg/kg of bodyweight per day of piperine, though higher concentrations may be toxic for the CNS and reproductive system.
  • Summary
    This was a review of 12 human, 16 animal, and nine in vitro studies assessing piperine for its primary therapeutic effects, optimal methods of extraction, and bio-enhancing abilities. The significant body of research supports the use of piperine for its antioxidant and anti-inflammatory effects with mention of a broad spectrum of associated secondary effects. Several studies show that piperine increases the bioavailability of curcumin, as well as other nutritional and botanical ingredients, thereby enhancing their therapeutic effects.

Rhodiola

  • Study Details
    Anghelescu I-G, Edwards D, Seifritz E, Kasper S. Stress management and the role of Rhodiola rosea: A review. Int J Psychiatry Clin Pract. 2018;22(4):242-252.
  • Study Design
    Systematic Review Analysis
  • Included Studies
    Four studies:  1 single center open label 1 randomized open label 1 open multi-center single arm 1 randomized, double-blind, placebo controlled cross-over
  • Study Duration
    Two to 12 weeks
  • Intervention(s)
    Rhodiola root extract (WS 1375 Rosalin) 200 mg BID – 3 studies Rhodiola root extract (SHR-5) 170 mg/d – 1 study
  • Control
    Placebo
  • Primary Outcomes
    Stress, fatigue
  • Results and Conclusion(s)
    All studies showed favorable results (Edwards et al. 2012); clinically relevant improvement in stress and fatigue, with significant improvement after 3 days (Darbinyan et al. 2007); less fatigue in active group vs placebo (Cropley et al. 2015); significant reduction in anxiety, stress with significant improvement in mood (Heldmann et al. 2016) increase in attention and working speed under duress.
  • Adverse Events
    No adverse events reported
  • Summary
    Review of four human based studies on R. rosea and its relationship to stress and fatigue. One trial was randomized and placebo-controlled. Each trial involved between 50-100 participants and lasted from 2-12 weeks in duration. All four studies showed favorable results with Cropley et al. (2015) showing significant improvement in symptoms of stress and Edwards et al. (2012) showing clinically relevant improvement in fatigue.

Ashwagandha

  • Study Details
    Chandrasekhar K, Kapoor J, Anishetty SA. A Prospective, Randomized Double-Blind, Placebo-Controlled Study of Safety and Efficacy of a High-Concentration Full-Spectrum Extract of Ashwagandha Root in Reducing Stress and Anxiety in Adults. Indian J Psychol Med. 2012;34(3):255-262.
  • Study Design
    Double-blind, randomized, placebo-controlled trial
  • Participants
    64 adults with chronic stress
  • Study Duration
    60 days
  • Intervention(s)
    Full-spectrum ashwagandha root extract (300 mg standardized root extract containing 5% withanolides; KSM-66) twice per day
  • Control
    Placebo containing an inert substance twice per day
  • Primary Outcomes
    To evaluate the safety and efficacy of ashwagandha root in reducing stress and anxiety and in improving the general well-being of adults who were under stress.
  • Results and Conclusion(s)
    The ashwagandha treatment group exhibited a significant reduction in scores on all stress-assessment scales and in serum cortisol levels, relative to the placebo group. The authors conclude that ashwagandha root extract safely and effectively improves an individual’s resistance towards stress and thereby improves self-assessed quality of life.
  • Adverse Events
    Mild adverse effects were comparable in both the treatment and control groups, including nasal congestion, cough and cold, drowsiness, and decreased appetite. No serious adverse events were reported.
  • Summary
    This study involves 64 participants ages 18–54 with chronic stress. A randomized, double-blind, placebo-controlled trial using 300 mg of ashwagandha (KSM-66 containing 5% withanolides) dosed two times daily over a 60-day period was compared to placebo. The primary outcome measure was to evaluate the safety and efficacy of ashwagandha root extract in reducing stress and anxiety and in improving the general well-being of adults who were under chronic stress. Assessments included three widely used sets of stress scales and serum cortisol levels, a biological marker of stress.

California Poppy

  • Study Details
    Hanus M, et al. Double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of a fixed combination containing two plant extracts (Crataegus oxyacantha and Eschscholzia californica) and magnesium in mild-to-moderate anxiety disorders.  2004 Jan;20(1):63-71.
  • Study Design
    Double-blind, randomized, placebo-controlled
  • Participants
    264 patients (81% female; mean age: 44.6 years) with generalized anxiety disorder
  • Study Duration
    3 months
  • Intervention(s)
    A combined formula containing California poppy herb dry aqueous extract (20 mg), hawthorn flower dry hydroalcoholic extract (75 mg), and magnesium oxide (75 mg) in each tablet. Two tablets were taken twice daily (Sympathyl; Laboratoire Innotech International, Arcueil, France)
  • Control
    Placebo
  • Primary Outcomes
    Anxiety (Hamilton anxiety ((HAM-A)) scale – total and somatic, self-assessment score) assessed before day 1 and on days 7, 14, 30, 60, and 90.
  • Secondary Outcomes
    Risk-benefit ratio (physician’s assessment).
  • Results and Conclusion(s)
    The intervention group had a rapid and progressive reduction in total anxiety score (p=0.005), somatic score (P=0.05) and in patient self-assessment (p=0.005), compared to placebo.
  • Adverse Events
    15 patients (11.5%) in the treatment group and 13 patients (9.7%) in the placebo group experienced adverse events, mainly mild or moderate digestive or psychopathological disorders.
  • Summary
    This was a double-blind, randomized, placebo-controlled study evaluating the effects of two tablets taken twice daily of Sympathyl, a commercially available product containing California poppy herb dry aqueous extract (20 mg/tablet) and two other primary ingredients on anxiety in 264 patients with generalized anxiety over a 3-month period. The primary endpoint was reduction in anxiety as assessed by the Hamilton anxiety scale, patient self-assessment score, and physician risk-benefit investigation assessed before day 1 and on days 7, 14, 30, 60, and 90. At the study’s conclusion, a highly statistically significant effect for the treatment group in comparison with the placebo group was observed in the Total Hamilton Anxiety Score (p=.005). The authors concluded that the combination “proved safe and more effective than placebo in treating mild-to-moderate anxiety disorder.”

Bring Rightful For Pain & Recovery to your practice and patients